A comparison of the pharmacokinetics and tolerability of riluzole after repeat dose administration in healthy elderly and young volunteers

Journal of Clinical Pharmacology

Volumn 39, Issue 5, 1999, Pages 480-486

  Le Liboux, Aimé ^a   Cachia, Jean Paul ^b   Kirkesseli, Stéphane ^b   Gautier, Jean Yves ^b   Guimart, Colette ^b   Montay, Guy ^b   Peeters, Pierre A M ^b   Groen, Edwin ^b   Jonkman, Jan H G ^b   Wemer, Johannes ^b  

^a SANOFI   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

RILUZOLE;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOLERABILITY; FEMALE; FLATULENCE; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUROTOXICITY; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PLASMA CLEARANCE; RHINITIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AGING; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; MALE; NEUROPROTECTIVE AGENTS; RILUZOLE;

EID: 0032781889     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Bryson HM, Fulton B, Benfield P: Riluzole: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis. Drugs 1996;52:549-563.
2. Doble A: The pharmacology and mechanism of action of riluzole. Neurology 1996;47(Suppl. 4):S233-S241.
3. Bensimon G, Lacomblez L, Meininger V, and the ALS/Riluzole Study Group: A controlled trial of riluzole in amyotrophic lateral sclerosis. New Engl J Med 1994;330:585-591.
4. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V for the Amyotrophic Lateral Sclerosis/Riluzole Study Group II: Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996;347:1425-1431.
5. Le Liboux A, Lefebvre P, Le Roux Y, Truffinet P, Aubeneau M, Kirkesseli S, Montay G: Single- and multiple-dose pharmacokinetics of riluzole in white subjects. J Clin Pharmacol 1997;37:820-827.
6. Sanderink G, Bournique B, Stevens J, Petry M, Martinet M: Involvement of human cytochrome P450 isoenzymes in the hepatic metabolism and drug interactions of riluzole in vitro. J Pharmacol Exp Ther 1997;282:1465-1472.
7. Leigh PN, Ray-Chaudhuri K: Motor neuron disease. J Neurol Neurosurg Psychiatry 1994;57:886-896.
8. WinNonlin, version 1.1. Scientif. Consulting, Inc. 8509 Burnside Drive Apex, NC 27502.
9. Boxenbaum H, Battle M: Effective half-life in clinical pharmacology. J Clin Pharmacol 1995;35:763-766.
10. Bruno R, Vivier N, Montay G, Le Liboux A, Powe LK, Delumeau J-C, Rhodes GR: Population pharmacokinetics of riluzole in patients with amyotrophic lateral sclerosis. Clin Pharmacol Therap 1997;62:518-526.
11. Wokke J: Riluzole. Lancet 1996;348:795-799.